Ivermectin, Fenbendazole and Mebendazole for Stage 4 Prostate Cancer: A Case Series of 40 Patients (May 2026 Update)

A Systematic Review of Case Reports on the Use of Ivermectin and Benzimidazoles (Fenbendazole and/or Mebendazole) in Stage 4 Prostate Cancer Treatment

Aug 09, 2025

Abstract

Background: The global burden of advanced prostate cancers remains a significant challenge, particularly in low- and middle-income countries where access to effective therapies is limited. Repurposing existing drugs, such as the antiparasitics ivermectin, fenbendazole, and mebendazole, has garnered attention due to anecdotal reports suggesting potential anti-cancer effects.

Objective: This article compiles and systematically presents anecdotal case reports and preliminary clinical data on the use of ivermectin and benzimidazoles (fenbendazole and mebendazole) in patients with stage 4 prostate cancers, aiming to provide a foundation for further scientific investigation.

Methods: Case reports were collected from various online sources, including social media platforms (e.g., X/Twitter) and websites, detailing patient experiences with ivermectin and benzimidazoles, often in combination with conventional therapies. Cases are organized with a focus on stage 4 prostate cancer diagnoses, and include reported outcomes such as tumor shrinkage, biomarker reduction, and imaging results.

Results: A total of 30+ case reports were compiled. Notable outcomes include significant tumor volume reductions, biomarker decreases (e.g., PSA dropping), and reports of “cancer-free” status in some cases.

Conclusion: These anecdotal reports suggest potential anti-cancer effects of ivermectin and benzimidazoles, warranting further investigation through rigorous clinical trials. Patients should consult oncology specialists to integrate these findings into personalized treatment plans, as the evidence remains preliminary.

Keywords: Ivermectin, fenbendazole, mebendazole, repurposed drugs, advanced prostate cancer, stage 4 prostate cancer, case reports, integrative oncology.

Introduction

Access to effective, cancer-specific therapies remains limited, particularly in low- and middle-income countries where cancer survival rates lag behind those in high-income settings due to inadequate funding and infrastructure (source, source). This has led to increased interest in repurposing existing drugs as more affordable alternatives. Exploring such options may provide valuable insights and potential solutions for expanding treatment accessibility, warranting further scientific investigation.

Unlike most prostate cancer diagnoses, for which the five-year survival rate is nearly 100 percent, the five-year survival rate for prostate cancer in the advanced stages may be less, depending on where the cancer has metastasized to.

For instance, with regional metastasis (meaning the cancer has spread to nearby lymph nodes, muscles or organs), the five year survival rate is nearly 100 percent, but distant metastasis (meaning the cancer has spread to areas of the body beyond the pelvis), has a five-year survival rate of just 37 percent, according to the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) database.

Traditional cancer therapies—including surgery, chemotherapy, radiation, targeted therapy, and immunotherapy—have relatively low documented survival rates and outcomes for advanced, metastatic and stage 4 prostate cancer.

Testosterone suppressant drugs such as leuprolide injections and apalutamide pills are used until the cancer no longer responds to hormone suppression, a state referred to as loss of hormone sensitivity. One of the most significant side effects of leuprolide injections is bone demineralization, which can occur at a high rate of up to 11% per year.

Enzalutamide and abiraterone are commonly used to treat various subtypes of prostate cancer, with treatment and monitoring tailored to each specific subtype. The primary subtypes treated with these agents are metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC). Androgen Receptor (AR) splice variant (AR-V7) is a specialized test for circulating tumor cells (CTCs) to detect the AR-V7 mutation, a known mechanism of resistance to enzalutamide.

However, treatment options remain limited for patients with other subtypes of stage 4 prostate cancer, particularly those with resistant or aggressive disease not amenable to current targeted therapies.

One emerging area of interest in recent years is the potential use of anti-parasitics such as ivermectin and fenbendazole or mebendazole (FBZ) as either a standalone treatment or a complementary therapy alongside conventional treatment for various forms of cancer.

The fenbendazole and ivermectin cancer protocol gained rapid interest over the past years following some advanced cancer success stories (more than 600 case reports in more than 20 cancer types).

Despite widespread anecdotal reports and social media coverage suggesting that ivermectin, fenbendazole, or mebendazole may have potential in treating metastatic cancer, there is currently insufficient peer-reviewed clinical evidence to support their use as mainstream anti-cancer agents. Anecdotal accounts circulated on social media platforms such as X (formerly Twitter) and Facebook are typically not indexed in scientific literature databases like PubMed or Google Scholar.

This article is a work in progress and aims to systematically compile anecdotal success stories and case reports, with the goal of building a stronger basis for scientific inquiry. By collecting and analyzing these narratives, we hope to encourage further research into the roles of ivermectin, fenbendazole (FBZ), and mebendazole as components of potential combination therapies for advanced prostate cancers.

Note: Given the complexity of cancer treatment, it is crucial for patients to consult a specialized oncology team to determine the most appropriate course of action for their specific diagnosis.

This compilation includes multiple case reports documenting the use of ivermectin and related benzimidazole anti-parasitics—such as fenbendazole and mebendazole—in the treatment of stage 4 prostate cancers.

Case Presentations

Tables 1 - 3 below provide a summary of the information for the 22 cases presented in this paper, including therapies used, dosage, outcome, and prior treatments. The 22 cases are organised into tables grouped by primary drug emphasis (FBZ-focused (Table 1), IVM-focused (Table 2), or combinations (Table 3)). Each table includes key details: case number, patient demographics, cancer details, protocol, outcomes, and notes. Grouped cases (e.g., 7-12) are listed individually for completeness.

Table 1: Fenbendazole (FBZ)-Focused Cases

Table 2: Ivermectin (IVM)-Focused Cases

Table 3: Combination (IVM + FBZ, Often with Adjuncts) Cases

Case 40 - 2026: 66 year old Texas Man with Stage 4 Prostate Cancer to bones

Dr William Makis posted on X.com in June 2026:

IVERMECTIN and FENBENDAZOLE Testimonial - 66 year old Texas Man with Stage 4 Prostate Cancer to bones reports after 8 months: healed bone metastases! No chemo, no hormones.

STORY:
66 year old Texas Man with Stage 4 Prostate Cancer to bones.

In June 2025 he started:

Ivermectin 1mg/kg/day
Fenbendazole 1500mg/day
No hormone therapy
No chemo
Only Targeted radiation

Results after 8 months:

Significantly improved bone metastases.
“The DR was very happy as he shared with us that, according to the MRI, all cancer is gone and all 6 fractures in my spine are completely healed!!
PRAISE THE LORD and THANK YOU! All of this progress was without any chemo or Lupron shots!”
“I only had one round of 5 treatments of pointed radiation to my fractured spine back in May 2025”.

Case 39 - 2026: 84 year old Florida Man with Stage 4 Prostate Cancer

Dr William Makis posted on X.com in May 2026:

IVERMECTIN and FENBENDAZOLE Testimonial - 84 year old Florida Man with Stage 4 Prostate Cancer Reports after 4 months: PSA 425 to 2.2, ALK Phos 3655 to 209!

Florida is already leading the IVERMECTIN Cancer Revolution!
STORY:
84 year old Florida Man with Stage 4 Prostate Cancer metastatic to bones.

In November 2025 he started:

Ivermectin 1mg/kg/day (84mg)
Fenbendazole 972mg/day
Hormone Therapy (Eligard, Nubeqa)

Results after 4 months:

PSA 425 to 2.2
ALP 3655 to 209

Let’s talk about repurposed drug safety.

An 84 year old cancer patient takes repurposed drugs Ivermectin and Fenbendazole with no issues.

I estimate that over 100,000 cancer patients are currently using Ivermectin, Fenbendazole, Mebendazole or some combination thereof, to enhance the effect of their cancer treatments.

Some of them are in their 80s. Some are in their 90s.

Yet mainstream Oncologists will still try to claim these safe repurposed drugs are somehow “dangerous” or “toxic”. Tell that to this 84 year old Florida man.

Another interesting thing to note:

Oncologists often combine drugs that are similar but have slightly different mechanisms of action.

Eligard and Nubeqa are used together in combination therapy to treat prostate cancer, but they work at opposite ends of the testosterone pathway.

Eligard acts upstream by stopping testosterone production, while Nubeqa acts downstream by blocking cancer cells from using testosterone.

Similar concept to combining Ivermectin with Fenbendazole.

Both are anti-parasitics but have different ways to attack the cancer. Combining them gives you a stronger treatment option.

Case 38 - 2026: 77 year old Arizona man with Stage 4 Prostate Cancer (Gleason 9)

Dr William Makis posted on X.com in May 2026:

18 month follow-up on 77 year old Arizona man with Stage 4 Prostate Cancer Gleason 9 taking Ivermectin and Fenbendazole!

We are now getting LONG TERM results! This is a must read.
STORY:
77 year old Arizona Man with Stage 4 Prostate Cancer, Gleason 9.

In December 2024 he started:

Ivermectin 1mg/kg/day
Fenbendazole 444mg/day (increased to 888mg/day)
Hormone Therapy

Results after 18 months (!!)

PSMA PET Scan results (as of 04-27-2026):

Bone Metastases mostly resolved with rib lesion remaining—SUV 2.9 to 1.2.

Tumors in the prostate have reduced in size

left side SUV 26.7 to 7.5
right side SUV 22.4 to 3.7.
External iliac lymph node metastasis SUV 40.5 (1.7 cm) to 3.8 (4 mm).
PSA - now 0.15 (down from 386)

We are now getting excellent long term results!!

78 year old man whose Stage 4 Prostate Cancer Gleason 9 continues to improve after 18 months on repurposed drugs.

Well tolerated long term! No side effects..

Case 37 - 2026: 75 year old man from SWEDEN with Stage 4 Prostate Cancer

Dr William Makis posted on X.com in May 2026:

IVERMECTIN and FENBENDAZOLE Testimonial - 75 year old man from SWEDEN with Stage 4 Prostate Cancer reports after 5 months: almost cancer free!

STORY: 75 year old man from SWEDEN with Stage 4 Prostate Cancer, Gleason 9, metastatic to bones. In November 2025 he started:

Ivermectin 1mg/kg/day
Fenbendazole 1500mg/day
Hormone Therapy: Casodex (Bicalutamide), Xtandi (Enzalutamide)

Results after 5 months:

“His PSA is (0.12)”
“his recent scan (X-ray and scintigraphy) showed that the metastasis in his backbone, pelvic bone and lung was gone, only like “scars” left, and the cancer in the prostate had diminished and was almost gone”
“I know that this has to do with the protocol”

Case 36 - 2026: 63 year old OHIO Man with Stage 4 Prostate cancer

Dr William Makis posted on X.com in April 2026:

IVERMECTIN, FENBENDAZOLE, MCP, CBD Testimonial - 63 year old OHIO Man with Stage 4 Prostate cancer - reports after 6 months - tumors shrinking!

Chemo avoided! Where a patient avoids chemo?

STORY 63 year old OHIO Man with Stage 4 Prostate cancer.

In July 2025 he started: Ivermectin, Fenbendazole, MCP, CBD Oil.

Results after 6 months: tumors shrinking, chemo avoided!

Case 35 - 2026: Family Member with Stage 4 Prostate Cancer (Testimonial from a California Doctor)

Dr William Makis posted on X.com in March 2026:

IVERMECTIN and FENBENDAZOLE Testimonial from a California Doctor - When a family member has Stage 4 Prostate Cancer and is told there is “no treatment”.

Important update: Most of the X.com (formerly Twitter) links from Dr William Makis now appear to be broken or inaccessible. This may be related to legal actions or regulatory proceedings involving Canadian authorities, although the exact reason for the link removals is not publicly clear. As a result, many of the original posts that were previously shared or cited on X.com are no longer available through their original links. The vast majority of the case reports, testimonials, and cancer-related discussions originally shared on X are mirrored (and actively updated) on his Substack: makisw.substack.com (published as “COVID Intel - by William Makis” / McGill Medicine branding).

Case 34 - 2026: 53 year old Connecticut man with Stage 4 Prostate Cancer

Dr William Makis posted on X.com in March 2026:

IVERMECTIN and FENBENDAZOLE Testimonial from a California Doctor - When a family member has Stage 4 Prostate Cancer and is told there is “no treatment”.

Case 33 - 2026: 53 year old Connecticut man with Stage 4 Prostate Cancer

Dr William Makis posted on X.com in March 2026:

IVERMECTIN and FENBENDAZOLE Testimonials - 53 year old Connecticut man with Stage 4 Prostate Cancer reported after 5 months - 99.9% drop in PSA, 50% tumor shrinkage.

53 year old Connecticut man with Stage 4 Prostate Cancer exercised his “Right to Try” repurposed drugs.

“PSA 99.9% drop in 6 months!”

“Oncologist says he’s “responding well” which we think is a massive understatement! Oncologist does not know he’s on the Ivermectin or Fenbendazole.”

Case 32 - 2026: 80 year old man in SAUDI ARABIA with Stage 4 Prostate Cancer metastatic to bones

Dr William Makis posted on X.com in February 2026:

IVERMECTIN, FENBENDAZOLE and MEBENDAZOLE Testimonial - 80 year old man in SAUDI ARABIA with Stage 4 Prostate Cancer metastatic to bones reports after 3 months: incredible response!

The Ivermectin Cancer Revolution has come to Saudi Arabia! How amazing is that? Who else can say that?

STORY: 80 year old man in SAUDI ARABIA with Stage 4 Prostate Cancer metastatic to bones.

In September 2025 he started Ivermectin and Mebendazole, and then Fenbendazole. Results over 4 months: PSA dropped 1277 to 8.69.

From patient’s family: “The Clinical response has been remarkable, and my local physician was very surprised by the degree of improvement observed”.

Case 31 - 2025: 66 year old TEXAS man with Stage 4 Prostate Cancer

Dr William Makis shared on X.com in November 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 66 year old TEXAS man with Stage 4 Prostate Cancer has a miraculous response after 4 months!

Warning - There is NO CHEMO in this story, so if you love chemo, please head to the nearest SAFE SPACE to cry. STORY: 66 year old TEXAS man with Stage 4 Prostate Cancer and extensive bone metastases Since April 28, 2025 he is taking:

Ivermectin 70mg
Fenbendazole 1554mg/day

Results after 4 months:

PSA 531 to 0.19
ALP 1709 to 53

“my spine neurosurgeon came in ECSTATIC to let me know my bones are healing greatly! The cancer was almost throughout my whole skeletal system. He thought I was taking CHEMO”.

Case 30 - 2025: 69 year old Canadian man with Stage 4 Prostate Cancer

Dr William Makis shared on X.com in October 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 69 year old Canadian man with Stage 4 Prostate Cancer has major improvement after 4 months! STORY: 69 year old Canadian man with Stage 4 Prostate Cancer On April 7, 2025 he started: Ivermectin 1.5mg/kg/day Fenbendazole 1500mg/day Results after 4 months: “liver metastases have improved significantly from previous exam”

“I am feeling a great improvement in energy, sleeping and overall well-being”

Case 29 - 2025: 68 year old California paraplegic man with Stage 4 Prostate Cancer

Dr William Makis shared on X.com in October 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 68 year old California man with Stage 4 Prostate Cancer was abandoned by Oncology as a paraplegic, after the cancer destroyed his vertebrae. He now walks.

Do you folks have any idea how many cancer patients have come to me after they were ABANDONED by their highly paid, licensed Oncologist? No one ever talks about that... 68 year old California man with Stage 4 Prostate Cancer was abandoned by Oncology as a paraplegic, after the cancer destroyed his vertebrae “I believe the hospital has written me off. The last time I saw the Oncologist in May, she was thinking I was “full of cancer” and hospice was probably next. So those were her plans, and she’s never contacted me again”. So he reached out to me. After we talked, on April 22, 2025 he started: Ivermectin 1mg/kg/day Fenbendazole 2000mg/day Results after 5 months: He went from being a paraplegic to walking PSA dropped 217 to 0.19 His metastatic bone pain has disappeared. “I’d always seen her in a wheelchair, and I walked into her office with a walker. I am currently back to walking.

Case 28 - 2025: 66 year old Australian man with Stage 4 Prostate Cancer

Dr William Makis shared on X.com in October 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 66 year old Australian man with 5 small children and Stage 4 Prostate Cancer sees “profound” improvement according to his urologist after 5 months Prostate Cancer patients are having incredible success with Ivermectin and Fenbendazole combination: 66 year old Australian man with 5 small children and Stage 4 Prostate Cancer His PSA was 736 In late March 2025 he started: Ivermectin 1mg/kg/day Fenbendazole 1776mg/day He had 2 Goserelin injections (hormone suppression) His PSA now is 15.1 and he is now a candidate for TURP and PAE Procedures He is working on getting an MRI. What have his doctors said about all this? That his treatment response has been “profound”.

Case 27 - 2025: 60 year old North Carolina man with Stage 4 Prostate Cancer to bones, Gleason 9

Dr William Makis shared on X.com in October 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 60 year old North Carolina man with Stage 4 Prostate Cancer to bones, Gleason 9, has amazing response after 6 months! I have wrapped up my Florida tour which means back to posting Ivermectin Cancer success stories! STORY: 60 year old North Carolina man with Stage 4 Prostate Cancer to bones, Gleason 9 In early November 2024 he started:

Ivermectin 108mg/day
Fenbendazole 1332mg/day
His doctor put him on hormone therapy

Results after 6 months:

PSA 196 to 0.16
50% reduction in metastatic lymph nodes

Case 26: Retired male civil fraud attorney with metastasised Stage 4 prostate cancer that had spread into his hip bones, lumbar spine, and inguinal lymph nodes (June 2025 update)

Mr. Jeffrey Kramer of Shelby, Ohio, retired as a plaintiff’s civil fraud attorney in 2024 after he was diagnosed with metastasized Stage 4 prostate cancer that had spread into his hip bones, lumbar spine, and inguinal lymph nodes. His Cleveland Clinic oncologist had advised him that the cancer was incurable but probably manageable for a (short) time using testosterone suppressant drugs (leuprolide injections and apalutamide pills) until his body ceased being “hormone sensitive,” at which point he would decline from there.

The side effects of that drug combo would be substantial—and potentially mortal. Most significant was that the leuprolide injection(s) would assuredly demineralize his bones at a high rate (up to 11% per year), leading to hip fracture(s) and loss of mobility.

This was Mr. Kramer’s second bout with serious cancer, as in 2010, he had undergone surgery, then three months of combined chemotherapy and radiation therapy for tonsil cancer that had incapacitated him for a year before he was able to resume his law practice.

Last fall, Mr. Kramer received information about a new cancer protocol that would change his life.

A new peer-reviewed cancer protocol authored by a team of sixteen cancer doctors and medical researchers from the US and several other nations was published in the September 2024 Journal of Orthomolecular Medicine, titled “Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol.” Its authors were prominent in oncology, and the published protocol was heavily footnoted to 204 medical studies documenting in vivo and in vitro safe and successful use of each and every element of the protocol. The authors of many of the referenced studies are at the top of their profession, i.e., well-known, highly published doctors and medical research professionals.

After carefully reading that report in the Journal of Orthomolecular Medicine, Mr. Kramer contacted three of the U.S./Canadian doctors who were co-authors of the protocol. Because the protocol had not yet been approved for clinical trials and therefore was not FDA approved, they explained that they could not provide assistance without risking discipline, including potential loss of license to practice medicine, by their state/province medical boards. In response to a question about when a clinical trial for this protocol would be approved, their answers were consistent: it typically would take ten to twenty years to get a clinical trial approved, especially where no Big Pharma company would have a profit interest to lobby for a clinical trial of a protocol involving repurposed/off-patent drugs.

Pierrick Martinez, of the Association Cancer et Métabolisme in Nimes, France, a medical researcher and lead author of the protocol, was then contacted by Mr. Kramer. He agreed to provide “long-distance assistance” and supervised administering the entire 15-week protocol, including corresponding with the nurse practitioner who administered the megadose vitamin C intravenous infusions that were one part of the protocol and answering numerous questions along the way. A licensed nutritionist at a Cleveland Clinic oncology center in Mansfield, Ohio, was consulted for advice on how to implement the therapeutic ketogenic diet that was another part of the protocol.

Mr. Kramer completed the 15-week hybrid orthomolecular protocol on June 5, 2025, with no side effects whatsoever. Two weeks later, he received an FDG-PET scan at AVITA Hospital in Galion, Ohio. The radiologist’s report that followed showed no evidence of any active cancer anywhere in his body—not in his head, hip bones, lumbar spine, chest, or lymph glands; nothing—no active cancer anywhere. In fact, it took the radiologist almost a full week to issue that report, for the PET scan was ordered to evaluate metastatic prostate cancer, deemed to be an incurable condition.

Perhaps most amazing, the total cost of the medicines, dietary vitamin/mineral supplements, and vitamin C infusions of this protocol was less than $20,000—a fraction of the cost of even one month’s expense for the cancer “management” medications that a Cleveland Clinic oncologist had previously prescribed as “the standard of care” for cancer treatment.

A mere $20,000 to stave off debilitating cancer and certain death was more than a bargain; it was a godsend to Mr. Kramer.

Source: Keto, Ivermectin, & Fenbendazole for Stage 4 Prostate Cancer: New Cancer Treatment Protocol Gains Momentum (American Greatness)

Case 25 - 2025: 58 year old man from WA, USA, with Stage 4 Prostate Cancer to bones, Gleason 9

Dr William Makis shared on X.com in September 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 58 year old man from WA, USA, with Stage 4 Prostate Cancer to bones, Gleason 9, reports after 3 months From the world’s largest Ivermectin Cancer Clientele: STORY: 58 year old man from WA, USA, with Stage 4 Prostate Cancer to bones, Gleason 9 In early March 2025, he started:

Ivermectin 1.5mg/kg/day
Fenbendazole 2000mg/day

It’s a little higher of a Fenbendazole dose than most cancer patients start with but this was a Stage 4 Gleason 9 and a young man who can handle these doses with no issues and no side effects.

Results after 3 months:

PSA 23.2 to below 1
Metastatic lymph nodes disappeared
Bone metastases healed over (sclerotic)

From the patient: “Thank you so much. The Lord lead me to your posted protocol early this year. Even though I had many times of fear and doubt, I believe God used your protocol to heal!”.

Case 24 - 2025: 64 year old Nevada man with Stage 4 Prostate Cancer metastatic to lungs and spine

Dr William Makis shared on X.com in August 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 64 year old Nevada man with Stage 4 Prostate Cancer metastatic to lungs and spine - PSA drops 79 to 0.32 after 4 months.

We have so many prostate cancer testimonials! STORY: 64 year old Nevada man with Stage 4 Prostate Cancer metastatic to lungs and spine Early February 2025 we started:

Ivermectin 1.5mg/kg/day
Fenbendazole 1500mg/day
CBD Oil 100mg/day

Results after 4 months: PSA 79 to 0.32.

Case 23 - 2025: 63 year old New York man with Stage 4 Prostate Cancer

Dr William Makis shared on X.com in August 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 63 year old New York man with Stage 4 Prostate Cancer reports after 4 months The testimonials will continue... 63 year old New York man with Stage 4 Prostate Cancer.

In early February 2025 we started:

Ivermectin 1.5mg/kg/day
Fenbendazole 1500mg/day
Oncologist put patient on Orgovyx and Nubeqa

RESULTS after 4 months: PSA 64.9 to less than 0.1.

From the patient: “Our May appointment with XXX went well, Oncologist very pleased with latest blood work results. So much so, potential chemo conversations have been postponed to potentially end of Summer”

Case 22 - 2025: Retired male civil fraud attorney with metastasized Stage 4 prostate cancer that had spread into his hip bones, lumbar spine, and inguinal lymph nodes (June 2025 update)

Source: Keto, Ivermectin, & Fenbendazole for Stage 4 Prostate Cancer: New Cancer Treatment Protocol Gains Momentum (American Greatness)

Case 21 - 2025: 74-yr-old man with Metastatic Prostate Cancer, Liver and Lymph Node Metastases

Published on Fenbendazole Can Cure Cancer (July 2025):

This is the account of a 74-year-old man, 6-ft, 169 pounds, who faced a dire prognosis of terminal, metastatic prostate cancer but charted an unconventional path to remarkable recovery, primarily through the determined use of fenbendazole. His journey told by his daughter TW, underscores a powerful testament to individual agency in the face of seemingly insurmountable odds.

The Onset of Crisis: A Timeline of Decline

TW’s dad’s battle with prostate cancer began in 2019, a diagnosis initially met with surgical removal of the prostate and an “all clear.” However, the reprieve was short-lived. The timeline of his relapse and subsequent crisis unfolded rapidly in 2024:

Early August 2024: Routine blood work delivered alarming news – a PSA of 14.
Mid-August 2024: The situation escalated dramatically. His PSA soared to 51, and asubsequent PET scan revealed the devastating spread: metastases to his liver and lymph nodes.
Late August 2024: Biopsies of both the liver and lymph nodes unequivocally confirmed the recurrence of prostate cancer.

The diagnosis from his oncologist at a leading cancer center (MDA) was grim: Stage 4 metastatic prostate cancer. He was informed that his liver was “completely consumed” and that medical intervention could offer nothing beyond palliative care. The proposed conventional treatment plan comprised hormone therapy (Lupron) followed by chemotherapy, with a stark prognosis of 12-18 months of life remaining.

A Divergent Path: Embracing Fenbendazole

Faced with this bleak outlook, TW’s dad’s made a pivotal decision. In September 2024, he received the initial Lupron shot as prescribed. However, during this consultation, he inquired about the fenbendazole protocol. His MDA oncologist unequivocally stated that if he chose to pursue fenbendazole, he could no longer be seen as a patient. Despite outwardly agreeing to forgo it, TW’s dad’s, resolute in his conviction, returned home and immediately initiated the fenbendazole protocol, choosing not to inform his oncologist.

His self-directed fenbendazole regimen commenced in late August 2024. He began with 222mg of fenbendazole (from Panacur C powder, meticulously weighed) once daily for seven days, quickly increasing to 222mg twice daily (total 444mg fenbendazole per day), taken after breakfast and dinner with peanut butter to aid absorption.

While fenbendazole was the central therapeutic agent, he adopted a comprehensive adjunctive strategy: a ketogenic diet (resulting in a 30-pound weight loss in three months), daily ivermectin (an eraser-sized amount of horse paste), Vitamin D, Serrapeptase, Soursop tea, TUDCA, Lion’s Mane, Onco Pathways 1-4 from UltraBotanica, high-dose intravenous Vitamin C (50-75 grams, three times a week), and monthly three-day fasts (water and bone broth only). Lupron remained the only conventional medical treatment he had ever received.

Immediate Impact and Astounding Turnaround

The effects of fenbendazole were felt almost immediately. Any existing pain and discomfort abated rapidly upon starting the fenbendazole, a profound and immediate improvement in his quality of life. Despite the grave diagnosis, TW’s dad’s reported feeling remarkably well throughout this period, never experiencing debilitating symptoms often associated with advanced cancer.

The true measure of fenbendazole’s efficacy became undeniably clear within three months.

Early November 2024: A follow-up appointment at MDA, initially intended to plan for chemotherapy, delivered astonishing news. A PET scan revealed a 50% reduction in all tumors. His oncologist was, by report, “shocked.”
Bloodwork corroborated this stunning reversal: his PSA, which had peaked at 51 in mid-August, had plummeted to just 2 by early November 2024.
The chemotherapy scheduled for that very day was promptly cancelled in light of these profoundly positive results.

Sustained Progress and Vigilant Management

TW’s dad’s continues his fenbendazole regimen (222mg twice daily, seven days a week) and the supportive protocols. He proactively monitors his liver enzymes (AST/ALT) through independent lab work, as these showed elevation on two occasions initially after starting fenbendazole. There were no adverse side effects attributed to fenbendazole. TW’s dad’s has not, and will not, disclose his fenbendazole use to his MDA oncologist.

His daughter, T.W., reported a further update from a follow-up visit at MDA on January 7, 2025:

His cancer showed an additional 50% decrease from the November scan. This marked a total 75% reduction in all tumors within just five months (August 2024 to January 2025) of commencing the fenbendazole-centric protocol. As of May 2025 there is no evidence of disease as confirmed by PET/CT scans.

TW’s dad’s speculates his cancer may have been linked to a diet high in sugar, processed foods, and carbohydrates, and potentially to COVID-19 vaccinations (two shots and one booster).

When sharing her Dad’s experience, TW said that reactions range from surprise and intrigue, with many requesting his protocol for loved ones, to indignation that such a potentially effective and accessible option is not offered by mainstream oncology.

“My Dad is doing amazing! He is still following the Joe Tippin's protocol and also uses Ivermectin and does high dose 100g Vit C IV's 3 days a week. His liver enzymes have been wonderful with no issues at all. He's stronger and more active now than he's ever been. He still eats all organic, no antibiotic or hormone foods and follows Keto; he even goes to the gym 4 days a week without question. He has zero size effects from any of the cancer or therapies we're doing. His next appt with MD Anderson is June 2025, we use them so we get the PET/CT scans and can track his progress. Here is a spreadsheet I put together showing his progress to date. To this day he has still had no radiation or chemo and doesn't plan to.”

Q: We are getting ready to publish your Dad’s story, did he happen to be taking aspirin in any form while self-treating with fenbendazole?
A: No aspirin.

““He had a follow up on 6/28 and another 30% reduction from last appointment. His cancer has digressed by 80% now overall. His tumors in the lymph nodes and lungs are now completely gone. MD Anderson is still tapping their foreheads asking “are you doing anything besides the lupron shot we gave you?” Of course we say no because Dad wants to still get the quarterly PET scans to track his progress.””

Summary

This Case Report documents the extraordinary turnaround of a 74-year-old man diagnosed in August 2024 with Stage 4 metastatic prostate cancer, with extensive liver and lymph node involvement, and given a palliative prognosis of 12-18 months. Forsaking further conventional treatment beyond an initial Lupron injection, he independently initiated a daily regimen of fenbendazole (444mg total). He experienced an immediate abatement of all pain and discomfort. Within three months, his PSA plummeted from 51 to 2, and imaging confirmed a 50% reduction in all tumors, leading to the cancellation of planned chemotherapy. After five months on fenbendazole, his total tumor burden had decreased by an astounding 75%, now NED in liver at 11 months. This remarkable outcome, primarily attributed by TW’s dad to fenbendazole, underscores the profound anti-cancer effects he experienced with fenbendazole.

Case 20 - 2025: 75-year-old man with recurrent stage IV prostate cancer and extensive bone metastases

Published peer-reviewed paper on Case Reports in Oncology (May 2025):

A 75-year-old man was diagnosed in December 2021 with recurrent stage IV prostate cancer and extensive bone metastases. Initially diagnosed 10 years earlier and treated surgically, he had undetectable PSA levels for 18 months before a gradual rise indicated recurrence of prostate cancer. The diagnosis of metastatic cancer was confirmed through imaging studies and elevated PSA levels. Bone scans and CT scans revealed metastases in the spine, pelvic bones, and right humeral head, along with significant lymph node involvement. On a CT abdomen/pelvis with and without IV contrast performed on December 16, 2021, prominent left periaortic lymph nodes were identified, with a representative lymph node measuring 0.8 cm, which was not seen in previous studies.

In December 2021, the patient initiated androgen deprivation therapy with Orgovyx and Erleada, complemented by Xgeva to support bone health. He also added repurposed medications and supplements: vitamin D (5,000–10,000 IU/day) with K2 and magnesium, melatonin (10–40 mg/day), berberine, curcumin, artemisinin, cimetidine, and other compounds with potential anticancer effects. He started taking FBZ in December 2021 (dose range: 222–444 mg/day), usually daily, with occasional dose reductions.
In December 2022, after 1 year of follow-up, regression of bone lesions was observed, and lymph node involvement had fully resolved. In January 2024, after 2 years of follow-up, imaging confirmed significant regression of bone lesions with no new metastatic sites. The use of FBZ coincided with continued regression of metastatic lesions and sustained undetectable PSA levels. No increase in liver enzymes or any other side effects attributable to FBZ were reported.
In April 2024, a PSMA-PET/CT whole body scan revealed that the vast majority of the sclerotic bone lesions demonstrated no abnormal radiopharmaceutical accumulation. A large left renal cortical cyst deforming the kidney had a SUV of 0.5, and no abnormal radiopharmaceutical accumulation was observed within lymph nodes. PSA levels remained undetectable for over 2 years (<0.05 ng/mL).
After 26 months of sustained regression and no new progression, the patient remains in near-complete response and continues FBZ with conventional therapy (androgen deprivation therapy with Xgeva). A summary timeline is provided in Figure below.

Case 19 - 2025: Alberta man with Prostate cancer, avoids radical prostatectomy and full pelvic radiation

Dr William Makis shared on X/Twitter in June 2025:

Ivermectin and Fenbendazole Testimonial - Alberta man avoids radical prostatectomy and full pelvic radiation, PSA 9.0 to 1.7 and doing great! An Alberta man was diagnosed with Prostate Cancer. He was offered the best options Modern Oncology has to offer: radical prostatectomy and full pelvic radiation. These treatments are 50+ years old...

His Alberta doctors also told him there was a 50% chance he would be "normal" after one of these procedures.

"I am in the risk business and this seemed unacceptable to me".

So he started Ivermectin and Fenbendazole, went to Seattle for Proton Therapy, and then continued Ivermectin and Fenbendazole with MCT Oil for 3 months. He did the opposite of what Modern Oncology recommended. How did he do?

"My PSA registered 1.7 (from a high of 9)...My prostate is still intact. All my bodily health functions are normal".

Case 18 - 2025: 77 year old North Carolina man with Stage 4 Prostate Cancer metastatic to lungs and bones

Dr William Makis shared on X/Twitter in June 2025:

IVERMECTIN and FENBEDAZOLE and CBD Oil Testimonial - 77 year old North Carolina man with Stage 4 Prostate Cancer metastatic to lungs, bones, has almost complete resolution of cancer after 5 months!! Want to see an incredible Prostate Cancer testimonial? According to vocal pharma shills, these don't exist 77 year old North Carolina man with Stage 4 Prostate Cancer metastatic to bones.

End of Nov. 2024 we started:

Ivermectin 1.5mg/kg/day
Fenbendazole 888mg/day
CBD Oil 50mg/day

His Oncologist put him on chemo

RESULTS after 5 months:

PET/CT done May 4, 2025 showed almost complete resolution of cancer!

Prostate: Previously near entirety of the gland was involved with intense radiotracer activity prostate adenocarcinoma. Single focus of radiotracer activity remains within the apex of the prostate gland SUVmax 4.8

Pelvic nodes - Single node in right external iliac nodal station SUVmax 2.6 measures less than 5mm. (Previously enlarged 10mm node with SUVmax 45).

Periaortic nodes - Resolution of previously seen periaortic retroperitoneal nodes (previous 13mm SUVmax 39.9 and 10mm SUV 44.6max, now gone)

Bones: only 3 foci remain in the skeleton. Interval resolution of previously described activity within the pelvis and lumbar spine. (previous sternoclavicular joint SUVmax 64.2, now SUVmax 8.3)

Lungs: resolution of left upper lobe pulmonary nodule (previous 4mm SUVmax 6.3)

From the patient:

"I am elated to write to you to express my gratitude for your help. My father got his results this week. The stage 4 prostate cancer is practically gone. The scan only shows 2-3 tiny spots on his bones and they’re not sure if that’s even cancer."

"My family is sooo happy. My dad is sleeping soundly now for the first time since the diagnosis back in August, 2024. I’m sure it’s because he doesn’t have the anxiety that comes with such a terrible diagnosis"

"I will never be able to repay you for saving my dad’s life. Thank you for your dedication to saving lives all over the world! Much love and respect!"

Case 17 - 2025: 87 year old WA man with Stage 4 Prostate Cancer metastatic to bones & spine

Dr William Makis shared on X/Twitter in June 2025:

IVERMECTIN and FENBENDAZOLE Testimonial - 78 year old Australian man with Stage 4 Prostate Cancer sees PSA 385 drop to 1.2 and tumors shrinking!

I have many Stage 4 Prostate Cancer success stories, although this is where I recently faced sabotage After all, Prostate Cancer means big money for Big Pharma, and they will send anyone, along with an entire army of bots to protect their profits

STORY: 78 year old Australian man with Stage 4 Prostate Cancer started chemotherapy (Docetaxel) and Hormone Therapy (Goserelin)

But he also came to me for help and started:

Ivermectin 1mg/kg/day
Fenbendazole 1000mg/day

After not even 2 months: PSA 385 to 1.2 Metastatic disease shrinking on PET/CT There are some prostate cancers, however, that are completely resistant to Ivermectin and Fenbendazole. Why they are resistant, I don’t know. There isn’t a particular identifiable feature. This remains one of the challenges. Many respond, but some don't. When they do respond, the response is very impressive.

Case 16 - 2025: 87 year old WA man with Stage 4 Prostate Cancer metastatic to bones & spine

Dr William Makis shared on X/Twitter in June 2025 :

IVERMECTIN and FENBENDAZOLE TESTIMONIAL - 87 year old WA man with Stage 4 Prostate Cancer metastatic to bones & spine, has dramatic response, PSA 2093 to 39, shocks Oncologist STORY: 87 year old WA man with Stage 4 Prostate Cancer metastatic to bones, with bone pain and severely reduced mobility. We started in late March 2025:

Ivermectin 1mg/kg/day
Fenbendazole 1000mg/day

RESULTS after 2 months: PSA 2093 to 39

From patient: April 4:

"My father got his bloodwork done and the good news is his testosterone & PSA is way down. He says the pain in his legs is a lot better as well. Things are looking up!"

April 13: "His PSA was 2093, now it is 83 on 4/1/25. He didn’t use his walker or cane when I took him for his healthy IVs. Just a little bit of pain in his legs, but much better."

April 18: "My father’s numbers are getting better so all is well. Just did more bloodwork on Thursday, April 17th and his PSA went from 85 down to 39."

May 21: "the good news is, the soon to be fired oncologist, was very surprised on how well my father is doing. He told my father whatever he was doing to keep doing it. He was VERY impressed."

"Last time he went to see the doctor he was using his walker and now he isn’t using his cane or walker!! So, my father is doing better thanks to you and my father’s diligent efforts in following the protocol."

Case 15 - 2025: Stage 4 Prostate Cancer

Dr. Peter McCullough shared (May 2025) a stunning anecdote: a patient with metastatic prostate cancer saw his PSA drop from 200 to 2 after trying ivermectin.

Case No. 14 - 2025: 93 year old male with Stage 4 prostate cancer that has metastasized to the hip bone

Testimonial shared by @1FidLaf in May 2025 (source):

"Well thanks to a miracle drug. That is very inexpensive. My 93 year old father is alive today. In just 2 months he was cured of a prostate cancer that has metastasized to the hip bone. IVERMECTIN is that miracle drug. It cost less that $80 dollars for the cure. No chemo no radio."

Source: https://x.com/1FidLaf/status/1920462322314703199

Case 13: Stage 4 prostate cancer

Dr. Kathleen Ruddy reported on a case of stage 4 prostate cancer:

He worked for the government, and he was going to lose his job and his pension if he wasn’t vaccinated. Two months after his second Pfizer shot, he was diagnosed all at once with stage 4 prostate cancer. He tells a very compelling, melodramatic story about that 24-hour period of time in his life.

He went through the traditional protocols; radiation, chemotherapy, pharmacologic, castration, all of it, over a period of nine months. His name is Paul Mann. His doctor said, “There’s really nothing else we can do. He said, “Can’t you give me more radiation? Can’t you give me more chemo? Aren’t there any other drugs? Are there any clinical trials? The answer was, “No, there’s nothing. There is only hospice. Send for the priest.”

A friend of his knew me and said, “Would you give Paul a call? He just needs some moral support.” I began calling him and we spoke about once a week for three weeks. The poor guy was suffering and had cancer in 11 bones in his body. His right leg was completely swollen and obstructed with a tumor. He was miserable.

I said, “Paul, I don’t know if this is going to help you, but I know it’s not going to hurt you. I just can’t imagine based on my judgment and understanding of the scientific literature and all of the work that Doctors Kory and Marik have done that ivermectin would hurt you. It might help, but I can’t say.”
He said, “I'll give it a try.” He drove to Tennessee where you could get it without a prescription. He drove from where he lives in New York to Tennessee and paid cash for his ivermectin. He didn’t submit it to an insurance company. He didn’t tell his oncologist back in Missouri.

His ivermectin prescriptions were listed in his medical chart. How did that information get from the pharmacy in Tennessee to his chart in Missouri? They don’t know. But actually, somebody does know, and I'd like to know myself.

Anyway, he starts taking ivermectin. He doesn’t have any problems with it. I talk to him every week, “How are you feeling? How’s your leg? How’s the pain? He says, “No change. But I don’t know. It’s not quite as swollen. There’s pain everywhere. Maybe it’s getting a little bit better. It’s not necessarily getting worse.”

Fast forward to a two-month follow-up appointment at the clinic. They didn’t expect to see him. He’s feeling a little bit better. They do a PSA [Prostrate-Specific Antigen Test], which in the beginning was off the charts, maybe 700 or 800. At the time, they recommended him to hospice.
Mr. Jekielek: What exactly do those numbers mean, for the layperson?

Dr. Ruddy: Over four would be abnormal. What are we talking about here? Prostate cells normally secrete a protein, a prostate-specific antigen. It’s one of the things that they do. Cancer cells that originate in the prostate that are dividing rapidly and growing fast are spitting out PSA. It’s not that they’re contributing to the body economy in any way. It’s just they just want to multiply and divide. That’s the end of the story.

Your PSA levels start to rise, which is a screening marker. They will say, “Your PSA was four, and now it’s eight. Let’s do a prostate ultrasound.” The PSA can be a screen for the emergence of a tumor, but it can also be used, particularly at high levels, as evidence for cancer, response to cancer, or recurrence of cancer. His was supposed to be four, but it’s in the hundreds.

He goes back for a two-month appointment and it’s 1.3. They said, “You’re in biochemical remission.” He was not in complete remission, because he still had the bone metastasis, but this was good news. Slowly, he begins to improve. There is less pain and the swelling is down. He has a lot of other vaccine injuries, but he’s getting better.

Cases 7 - 12: Cases shared by Dr William Makis (X/Twitter) in February 2025:

Case 01: 78 year old man with Prostate Cancer Gleason 9 post prostatectomy, halted recurrence with "your low dose protocol" "So there you have it. My PSA has stopped rising, still 1.2 and my annual scan and MRI in December were still clear after 3 months on the low dose protocol".

Case 02: "Stage 4 Prostate fighter/survivor. On Iver and Fenben for 19 months. Cancer undetectable for past 12 months".

Case 03: Brig Gen (Ret) USAF: "my prostate cancer was eradicated using IVM, Fenben and Doxy".

Case 04: "I have more positive results to report!" "My husband got his PSA results back today. When he was diagnosed with prostate cancer his PSA was 5.8 now it is down to 4.1 after 32 days on Ivermectin and Fenbendazole".

Case 05: "I was told by one local oncologist that I had 2 months to 2 years max" "This past summer moved to high dose Ivermectin and I feel a huge improvement. I take 48-60mg daily and that had the affect of depressing my PSA significantly. But again, the real measure is I feel so much better".

Case 06: "Praise the Lord for Dr.Makis and his wisdom, kind compassionate heart and generosity!! Wonderful start to a Happy New Year!".

"My husband has recently been diagnosed with Prostate Cancer. We started: Daily IVM 96mg 3x/week fenben 888mg LDN Orgovyx PSA 538 (12/6/24) down to 290 (12/30/24).

"God Bless you and your beautiful family Dr.Makis!".

Case 6: Stage 4 Prostate Cancer

Testimonial shared by Jaquar-2014- (HealthUnlocked) in 2024:

I was diagnosed with stage four prostate cancer at the end of January 2024, with a PSA of 143 and a 9 on the Gleason score. It had metastasized to several parts of my bones. I immediately started the Joe Tippens protocol.

Two months later, my PSA dropped to 26. For the last four months, my PSA has been zero. My doctor says I don’t need an MRI or PET scan because I have no evidence of cancer. I do have to undergo some radiation for the cancer on the bones.

So, on the dog medicine, I am cancer-free. This is the truth—no side effects and feeling good. If you’re interested in beating any kind of cancer at any stage, the Joe Tippens story was my cure.

Case 5: 79 year old Canadian man with Stage 4 Prostate Cancer to Lymph nodes (December 2024)

Case shared by Dr William Makis (X/Twitter):

IVERMECTIN and FENBENDAZOLE Testimonial - 79 year old Canadian man with Stage 4 Prostate Cancer to Lymph nodes - everything is shrinking 4 months later! 79 year old British Columbia, Canada man diagnosed with Prostate Cancer, Gleason 8, “pushing against bladder wall, in lymph nodes, diagnosed late 2022 with a PSA peaking at 19.72. Completed 28 treatments of radiation. Was currently on hormone blockers (and Abiraterone) but tumor hasn’t shrunk. Came to me for help and we got to work right away:

We started the following protocol:

Ivermectin 1mg/kg/day
Fenbendazole 444mg/day
Melatonin 120mg/day
IP6
Artemisia

RESULTS:

“approaching 4 months on Ivermectin plus the other products”

“the oncologist report is that there is shrinkage in all areas (prostate, bladder wall and lymph nodes. He is not in remission as yet”.

The answer to the question is: continue Protocol until remission.

Case 4: Stage 4 Prostate Cancer patient - PSA drops 1533 to 968 in 12 days (November 2024)

Case shared by Dr William Makis (X/Twitter):

IVERMECTIN and FENBENDAZOLE Testimonial - Stage 4 Prostate Cancer patient - PSA drops 1533 to 968 in 12 days - is fatigue and bone pain normal?

Stage 4 Prostate Cancer patient: Started Ivermectin 1mg/kg and Fenbendazole 1000mg 3 days on 4 days off. In 12 days PSA drops 1533 to 968 (37% drop). Abdominal cancer lymph nodes disappeared.

To be honest, that’s a lot of cancer cell killing over a very short period of time!! That will cause a great deal of FATIGUE. That’s to be expected. Bone pain? Also. As cancer cells in bone get killed, the inflammation can also cause bone pain. That will heal over time. This gentleman is on his way to becoming cancer free.

Case 3: November 2024

Case sharing by Dr William Makis (X/Twitter):

IVERMECTIN and FENBENDAZOLE Testimonial - Stage 4 Prostate Cancer patient from Ecuador, Gleason 8, goes on Protocol and PSA drops from 800 to 18 in 3 months!

Patients from around the world (hello Ecuador!) are benefiting from Ivermectin and Fenbendazole repurposed drug combination Protocols.

This was an Intermediate Dose Protocol, with a starting dose of Ivermectin of 1mg/kg/day and a Fenbendazole dose of 222mg to 444mg a day.

Additional benefit with a ketogenic diet! Now this is only 3 months in, but I think PSA 800 to 18 is good progress so far.

Case 2: Stage 4 Prostate Cancer (October 2024)

According to Dr William Makis (X/Twitter):

IVERMECTIN & FENBENDAZOLE in very aggressive Stage 4 Prostate Cancer

"We reached our goal of bringing my PSA Score down to 0.02 quite quickly. Doctors were surprised at how quickly this happened."

Case No.1: Stage 4 prostate cancer (September 2022)

My husband was diagnosed 8 months ago.. Feb 1st of this year,, with a aggressive form of prostate cancer that had already metastasized into his lymph nodes and bones. He had fractures throughout his spine, ribs and pelvis. Adams bone scan showed cancer in his bones from his skull,, facial bones, clavicle, sternum right rib cage and most of his spine and pelvis.. His oncologist (we’ve since changed) waited 7 weeks to start any hormone therapy or chemotherapy and told us radiation wasn’t even an option. Only 6 rounds of doxi. He sat at our first office visit Feb 2nd and told my family that the #1 man in our lives would be gone within 18 months. His psa was 140, Gleason score of 9. He was diagnosed full blown stage 4-5 cancer. This was completely unacceptable. Absolutely devastating to our world. My husband is 55 yrs old.. We have 8 children and 8 grandchildren. Our last 2 kids had just moved out a year before.. this was our time.. We had always talked about IF cancer ever came about for either of us we would research alternative treatments. We fear medical poison as much as the cancer itself..

Thank God my husband’s cousin connected us with a angel that gave us all the information we needed on a product meant for animals, fenbendazole and even sent us 2 bottles of fenbendazole. Has since supplied us with bottles when needed.

So week 2 post diagnosis Adam started his 222mg of fenben.

Read More: Fenbendazole and Ivermectin for Prostate Cancer Success Stories (including other stages of Prostate Cancer)

Discussion

Stage 4 prostate cancer, defined by distant metastases, has a 5-year survival rate of 37% with SOC treatments, including ADT, chemotherapy (e.g., docetaxel), and radiopharmaceuticals (e.g., Lu-177-PSMA-617).

The compiled case reports suggest potential anti-cancer effects of ivermectin and benzimidazoles, often in combination with conventional therapies. Reported mechanisms include inhibition of the WNT-TCF pathway [4], induction of apoptosis, and chemosensitization/radiosensitization [5, 6]. Notable outcomes include significant biomarker decreases (e.g., PSA from 2093 to 39), and improved quality of life. However, these reports are anecdotal, lacking the rigor of controlled clinical trials, and are subject to biases such as self-selection and incomplete follow-up.

Differences in response rates (e.g., variable efficacy in prostate cancer) and optimal dosing (e.g., higher doses of ivermectin at 1-2 mg/kg/day vs. lower doses in some cases) highlight the need for standardized protocols. Additionally, the cost-effectiveness of fenbendazole (~$0.48 per 222 mg dose) compared to mebendazole (~$450 per pill in the US) underscores the potential for accessible therapies, particularly in resource-limited settings.

The anecdotal nature of these reports limits their generalizability. Lack of control groups, variable treatment protocols, and potential confounding from concurrent therapies (e.g., chemotherapy, immunotherapy) complicate attribution of outcomes to ivermectin or benzimidazoles. Furthermore, social media sources are not indexed in scientific databases, increasing the risk of misinformation.

In a simulated randomised controlled trial (12), Ivermectin, Mebendazole, Metformin, High-Dose Vitamin C, Vitamin D, Curcumin, Diet/Lifestyle, and Standard Therapies significantly surpasses SOC (standard of care), with a 63% 5-year survival rate for Non-BRCA-Mutated Stage 4 Prostate Cancer.

The convergence of simulation data and clinical anecdotes points to a promising therapeutic role for ivermectin, mebendazole, fenbendazole, and related adjuncts in advanced prostate cancer. Mechanistically, ivermectin’s mitochondrial targeting and glycolysis inhibition, combined with benzimidazole-induced microtubule destabilization and apoptosis, may potentiate antitumor effects. Additional metabolic modulation by metformin and antioxidant support via vitamin C and curcumin potentially enhance therapeutic efficacy and patient well-being.

Although these data are encouraging, limitations include the inherent constraints of simulation models and the anecdotal nature of the case reports, which lack randomization and controls. Risks of drug interactions and toxicity at higher doses require careful evaluation. Future prospective, controlled clinical trials are imperative to validate these findings, optimize dosing, assess long-term safety, and define biomarkers for patient selection.

Conclusion

In conclusion, fenbendazole and ivermectin represent promising adjuncts in prostate cancer treatment, particularly for patients with limited therapeutic options. Simulation and real-world evidence indicate potential survival and quality-of-life benefits surpassing current SOC (standard of care) for stage 4 prostate cancer.

However, it is important to recognize that much of the current evidence is based on case reports, which provide preliminary insights but may be dismissed by some as anecdotal or of low scientific quality. Despite skepticism, these encouraging testimonials could signify the early stages of a scientific frontier worthy of rigorous exploration.

Well-designed clinical research is essential to determine whether these agents have a safe and effective role in prostate cancer treatment beyond isolated case experiences. Until such data are available, patients and clinicians should continue to rely on established, evidence-based therapies, while any off-label drug use should be carefully considered within structured clinical trials—including N-of-1 designs— with appropriate specialist oversight and proper consent form to safeguard the practitioners.

For a more comprehensive understanding, patients and clinicians are encouraged to review emerging research and participate in ongoing clinical trials. As always, treatment decisions should be made in close consultation with healthcare providers, with individualized monitoring and personalized care to optimize safety and efficacy.

FAQ

For questions related to this article: Ask AI Assistant.

Important Disclaimers:

Statements on this website have not been evaluated by the Food and Drug Administration. The contents of this website is for educational and informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis or treatment.
This work is for informational and research purposes only and does not constitute medical advice. Patients should consult healthcare providers before initiating any treatment.

Acknowledgments

The authors acknowledge the contributions of patients and advocates who shared their experiences on public platforms, as well as researchers like Dr. William Makis for their efforts in documenting these cases.

References:

https://www.weforum.org/stories/2024/03/global-cancer-funding-shortfall/
https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services
Yuan Y, et al. Phase I/II study of ivermectin and balstilimab in metastatic triple-negative breast cancer. J Clin Oncol. 2025;Abstract e13146.
Melotti A, et al. The river blindness drug ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer. EMBO Mol Med. 2014;6(10):1263-1278.
Mudassar F, et al. Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas. J Neurooncol. 2020;147(2):393-403.
Zhang L, et al. Mebendazole potentiates radiation therapy in triple-negative breast cancer. Int J Radiat Oncol Biol Phys. 2019;103(1):195-207.
https://www.medicalnewstoday.com/articles/326031
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2794946
https://ar.iiarjournals.org/content/44/9/3725
https://pmc.ncbi.nlm.nih.gov/articles/PMC7505114/
https://pmc.ncbi.nlm.nih.gov/articles/PMC9862092/
AI Predicts Ivermectin, Mebendazole, Metformin, High-Dose Vitamin C, Hyperthermia and More for Stage 4 Prostate Cancer (2025): A Simulated Randomized Controlled Trial (2025)
Fenbendazole and Ivermectin for Cancer: Real Stories, Science & Protocols (2025 Comprehensive Guide)
Ivermectin, Fenbendazole, and Mebendazole for Stage 4 Cancer: 310+ Case Reports Compilation (2026 Edition)
Fenbendazole and Ivermectin for Prostate Cancer (including other stages of Prostate Cancer): 120+ Case Reports

The Wellness Company's Ivermectin and Mebendazole

Ivermectin and mebendazole, both approved for human use, are now available in the U.S.

Researched and approved by Dr. Peter McCullough.

Prescribed by licensed medical professionals
Compounded and dispensed by a licensed US-based pharmacy
Approved for human use

Where to buy Ivermectin and Mebendazole Formula: Available on The Wellness Company's website. Here is the link: Ivermectin and Mebendazole.

One Day MD’s Newsletter

Discussion about this post

Ready for more?